Welcome to our dedicated page for Schrodinger news (Ticker: SDGR), a resource for investors and traders seeking the latest updates and insights on Schrodinger stock.
Schrodinger, Inc. (symbol: SDGR) is a top-tier provider of state-of-the-art molecular simulations and enterprise software solutions, catering primarily to the pharmaceutical, biotechnology, and materials science industries. With its pioneering software, Schrodinger empowers scientists to accelerate research and development, cut down on research expenses, and make groundbreaking discoveries that might not be feasible otherwise.
Established in 1990, Schrodinger has continually invested in fundamental research, leading to numerous scientific breakthroughs in drug discovery and materials science. The company's researchers have contributed hundreds of peer-reviewed scientific publications, often cited as significant works in their respective fields.
Schrodinger operates through two main segments: Software and Drug Discovery. The Software segment focuses on selling advanced software that revolutionizes drug discovery across the life sciences industry. It also caters to customers in materials science. The Drug Discovery segment generates revenue from a portfolio of preclinical and clinical programs, both internally developed and through collaborations.
Schrodinger has established profound partnerships and collaborations with companies in biotechnology, pharmaceuticals, chemicals, and electronics. One notable collaboration is with Nimbus Therapeutics, a biotech firm co-founded by Schrodinger. The company's global presence includes operations in the U.S., Europe, Japan, and India.
Recent achievements highlight Schrodinger's continuous innovation and success. The predictive power of its software solutions has led to significant advancements in scientific research, enhancing the efficiency and efficacy of drug discovery processes. Schrodinger's commitment to excellence and scientific integrity ensures it remains at the forefront of its industry, driving forward the boundaries of what is possible in molecular simulations and drug discovery.
Schrödinger (Nasdaq: SDGR) announced the granting of stock options to 14 new employees on July 15, 2021, totaling 32,975 shares. These options, part of the 2021 Inducement Equity Incentive Plan, have an exercise price of $67.46, matching the closing stock price on the grant date. The options vest over four years, with 25% vesting after one year and the remainder vesting monthly over the following three years. This initiative aims to attract talent and is compliant with Nasdaq Listing Rule 5635(c)(4).
Schrödinger (Nasdaq: SDGR) is set to present at two investor conferences in July 2021. The first presentation will occur on July 20, 2021, at the Evercore ISI AI x Therapeutics Day at 1:30 PM ET. The second presentation is scheduled for July 28, 2021, at the SVB Leerink CybeRx Conference at 2:00 PM ET. Schrödinger's innovative physics-based software platform enhances the discovery of therapeutics and materials, allowing for faster and cost-effective development.
Schrödinger, Inc. (Nasdaq: SDGR) announced on June 13, 2021, the grant of non-statutory stock options for 32,850 shares to 14 new employees. This action, part of the 2021 Inducement Equity Incentive Plan, was aimed at encouraging the employees to join the company. Each option has an exercise price of $77.51, equal to the stock's closing price on June 11, 2021. The options vest over four years, with a portion vesting after the first year and the remainder in monthly installments thereafter. Schrödinger continues to leverage its software platform for innovative drug and materials discovery.
Schrödinger (Nasdaq: SDGR) announced its participation in two upcoming virtual conferences. Management will present at the Jefferies Virtual Healthcare Conference on June 1, 2021, at 3:00 p.m. ET, followed by a presentation at the Goldman Sachs 42nd Annual Global Healthcare Conference on June 8, 2021, at 4:40 p.m. ET. Both presentations will be accessible on Schrödinger’s website under 'News & Events' for approximately 14 days. Schrödinger's innovative software platform accelerates the discovery of therapeutic and material solutions.
Schrödinger, Inc. (Nasdaq: SDGR) announced on May 15, 2021, the granting of stock options to 11 newly hired employees, totaling 22,775 shares. The options, part of the 2021 Inducement Equity Incentive Plan, have an exercise price of $61.24 per share and vest over four years. This initiative aims to attract talent by enhancing employment compensation. Schrödinger is known for its physics-based software platform that accelerates therapeutic and material discovery, aiding various sectors globally.
Schrödinger, Inc. (Nasdaq: SDGR) reported first-quarter 2021 financial results, noting a 23% increase in revenue to $32.1 million compared to Q1 2020. Software revenue grew 11%, while drug discovery revenue surged from $2.4 million to $5.8 million. Gross profit rose to $16.2 million despite a decline in software gross margin to 78%. Operating expenses increased significantly to $40.1 million. The company continues to advance its internal drug discovery pipeline and has expanded its collaboration with AstraZeneca. For 2021, Schrödinger expects total revenue between $124 million and $142 million.
Schrödinger (Nasdaq: SDGR) is set to present a corporate overview at the Bank of America Securities 2021 Virtual Healthcare Conference on May 11, 2021, at 3:30 pm ET. This innovative company is revolutionizing therapeutic and material discovery through its advanced physics-based software platform, allowing for faster and cost-effective development of high-quality molecules. The live webcast will be available in the investors section of Schrödinger’s website and will be archived for 14 days. Founded in 1990, Schrödinger has over 450 employees and operates globally across more than 70 countries.
Schrödinger (Nasdaq: SDGR) will host a conference call and webcast on May 11, 2021, at 8:30 a.m. ET to discuss its first quarter 2021 financial results and provide a business update. The live event can be accessed via the company's investor relations page. Schrödinger utilizes a physics-based software platform for rapid and cost-effective discovery of therapeutics and materials, serving biopharmaceutical companies, academic institutions, and government laboratories globally. Founded in 1990, the company operates with over 450 employees across more than 70 countries.
On April 13, 2021, Schrödinger, Inc. (Nasdaq: SDGR) granted non-statutory stock options for 7,450 shares to three new employees as part of their compensation under the 2021 Inducement Equity Incentive Plan. The options have an exercise price of $75.53 per share and a ten-year term, with a four-year vesting schedule. Schrödinger's physics-based software platform enhances the discovery of therapeutics and materials more efficiently than traditional methods. The company, founded in 1990, has over 450 employees and operates globally across various sectors.
Schrödinger (Nasdaq: SDGR) showcased promising preclinical data for its CDC7 inhibitor program at the AACR Annual Meeting on April 10, 2021. The data revealed that the company's picomolar CDC7 inhibitors effectively inhibited tumor cell growth, both individually and in conjunction with existing cancer treatments. The inhibitors demonstrated strong selectivity by inducing cancer cell apoptosis while sparing healthy cells, particularly in mouse models of acute myeloid leukemia and colorectal cancer. Schrödinger plans to advance these findings into IND-enabling studies in 2022.
FAQ
What is the current stock price of Schrodinger (SDGR)?
What is the market cap of Schrodinger (SDGR)?
What does Schrodinger, Inc. do?
When was Schrodinger, Inc. founded?
What are the main segments of Schrodinger’s business?
How does Schrodinger generate revenue?
What industries does Schrodinger’s software cater to?
What are some of Schrodinger’s recent achievements?
Where are Schrodinger’s operations located?
What is Nimbus Therapeutics?
How has Schrodinger contributed to scientific research?
What makes Schrodinger's software unique?
